GLB1 is a validated marker for senescence-associated β-galactosidase (SA-β-gal) activity, distinguishing it from other lysosomal enzymes . In prostate cancer (PCa), elevated GLB1 expression correlates with:
Lower tumor stage (p = 0.01)
Localized vs. metastatic disease (p = 0.0003)
GLB1 antibodies enable quantitative imaging in FFPE samples using platforms like Vectra and AQUA. Key findings include:
Tissue Type | GLB1 Expression | Senescence Correlation |
---|---|---|
High-grade PIN (HGPIN) | High (72% positive) | Strong (p < 0.01 vs. benign) |
Primary PCa | Moderate (37% positive) | Inverse with metastasis (p = 0.003) |
Benign Prostate | Low (13% positive) | None |
Data adapted from PLOS ONE studies .
In intermediate-grade PCa (Gleason 6–7), high GLB1 expression predicts:
Outcome | Low GLB1 | High GLB1 | p-value |
---|---|---|---|
PSA-Free Survival (Days) | 629 | 2314 | 0.013 |
Tumor Heterogeneity | High | Low | <0.001 |
Adapted from survival analyses in PLOS ONE .
GLB1 antibodies are available as polyclonal (rabbit) or monoclonal (mouse) reagents, with varying reactivities:
Sensitivity: Detects both active and inactive GLB1 isoforms.
Specificity: Minimal cross-reactivity with non-lysosomal β-galactosidases.
Validation: Tested in replicative senescence models and therapy-induced senescence (e.g., AZQ-treated PCa cells) .
A study on Glb1 homologue antibodies (targeting a wheat protein homolog) found no association with islet autoimmunity in type 1 diabetes but noted:
Factor | Association | p-value |
---|---|---|
Breastfeeding Duration | Inverse (cases only) | 0.001 |
Gluten Intake | Direct (cases only) | 0.007 |
Zonulin (gut permeability) | Direct (cases only) | 0.003 |